Recombinant Insulin Lispro Injection Market

The main component of recombinant insulin lispro injection is insulin lispro, which is a human insulin analog produced by genetic recombination technology. It is produced by exchanging the 28th and 29th amino acids on the insulin B chain. It is suitable for the need for insulin Adult diabetic patients who maintain euglycemic homeostasis
Recombinant Insulin Lispro Injection Market contains market size and forecasts of Recombinant Insulin Lispro Injection in global, including the following market information:
Global Recombinant Insulin Lispro Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Recombinant Insulin Lispro Injection Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Insulin Lispro Injection companies in 2021 (%)
The global Recombinant Insulin Lispro Injection market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
1ML Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Insulin Lispro Injection include GT, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Novo Nordisk, Pfizer, BI, Sanofi, Takeda Pharmaceutical Company and Wanbang Biopharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Insulin Lispro Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Insulin Lispro Injection Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Insulin Lispro Injection Market Segment Percentages, by Type, 2021 (%)
1ML
3ML
10ML
Global Recombinant Insulin Lispro Injection Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Insulin Lispro Injection Market Segment Percentages, by Application, 2021 (%)
Hospital
Pharmacy
Global Recombinant Insulin Lispro Injection Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Insulin Lispro Injection Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Insulin Lispro Injection revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Recombinant Insulin Lispro Injection revenues share in global market, 2021 (%)
Key companies Recombinant Insulin Lispro Injection sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Recombinant Insulin Lispro Injection sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GT
Tonghua Dongbao Pharmaceutical
Eli Lilly and Company
Novo Nordisk
Pfizer
BI
Sanofi
Takeda Pharmaceutical Company
Wanbang Biopharmaceuticals
United Laboratories